A Moderna-Merck melanoma vaccine win has turned tumor sequencing into a contested prize, pushing Personalis shares above Tempus AI's $16.25 offer after the target fielded a higher $17 rival bid. The $1.5 billion deal's real value lies in the recurring MRD blood-testing market dominated by Natera.
Moderna and Merck's positive late-stage melanoma results for their personalized mRNA cancer vaccine added more than $50 billion in combined market value to the two drugmakers, yet the clearest spillover is landing in a corner of healthcare that rarely draws a crowd: tumor sequencing. The readout has turned Tempus AI's $1.5 billion acquisition of sequencing partner Personalis into a contested prize, with Personalis shares trading above the offer price and the target having fielded a higher rival bid before agreeing to the deal.
"Personalis gives Lefkofsky a legitimate seat at the precision cancer-treatment table," said Douglas Eby, chief executive of Bioaxia, a life sciences value investment firm that holds shares in both Tempus AI and Personalis. "But first, he has to get the deal done, and the market is betting it won't be a smooth ride there."
The auction dynamics surfaced in the proxy Tempus AI released this week. Personalis, which has handled tumor sequencing for Moderna's clinical program, entertained multiple suitors and received a verbal proposal of $17 a share before accepting Tempus AI's $16.25 offer on July 20. Personalis shares have since climbed as high as $18, a rare premium to an acquisition price that typically signals investors are wagering on a sweetened offer or a competing bidder. Wall Street analysts have floated Natera and Guardant Health as potential interested parties. Tempus AI holds a 12 percent stake, and Merck has agreed to vote its 13 percent holding in favor of the deal, locking up roughly a quarter of voting power behind the transaction.
The strategic prize behind the sequencing fees explains the fight. Personalized cancer therapies require a genetic road map for each patient, and the tumor must be sequenced to identify the mutations a vaccine should target. Tempus AI has confirmed it will be the sequencing partner if the Moderna-Merck vaccine wins regulatory approval. Piper Sandler estimates at least $50 million in annual sequencing revenue if the vaccine is approved for melanoma alone, while BTIG analyst Mark Massaro projects that figure could exceed $600 million if the approach expands to lung, bladder and kidney cancers.
The larger opportunity sits in minimal residual disease, or MRD, a blood test that scans for traces of circulating tumor DNA after treatment and can flag recurrence before it appears on imaging. Investors view MRD as a multibillion-dollar market, most of it controlled by Natera, a roughly $45 billion company. Eby sees the mRNA business as a customer-acquisition funnel: the initial sequencing brings a patient into the Tempus ecosystem, while recurring MRD testing keeps them returning for years of monitoring. That recurring-revenue model is what Tempus founder Eric Lefkofsky needs to escape a valuation discount that has made the company one of the most shorted stocks in healthcare, trading at about six times expected sales versus roughly 13 times for faster-growing peers.
The clinical foundation is not yet secure. Moderna's stock surged 177 percent on Aug. 19, its largest single-day gain since its initial public offering, after the Phase 3 INTerpath-001 trial in 1,137 patients with resected high-risk melanoma met its primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. Yet just over a week later, rival BioNTech terminated a mid-stage colorectal cancer trial of its own personalized vaccine after an independent safety board found more deaths in the vaccine arm. The divergent outcomes show that clinical risk in the mRNA cancer space remains unresolved, and the durability of the sequencing tollbooth depends on whether drugmakers eventually bring some sequencing in-house or split the work among competing labs. For now, the market is pricing the tollbooth as worth fighting over, and the fight is not over.
